Cetrotide

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

cetrorelix (as acetate)

Disponibbli minn:

Merck Europe B.V.

Kodiċi ATC:

H01CC02

INN (Isem Internazzjonali):

cetrorelix

Grupp terapewtiku:

Pituitary and hypothalamic hormones and analogues

Żona terapewtika:

Ovulation; Ovulation Induction

Indikazzjonijiet terapewtiċi:

Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques.In clinical trials, Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.

Sommarju tal-prodott:

Revision: 27

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

1999-04-12

Fuljett ta 'informazzjoni

                                18
B. PACKAGE LEAFLET
19
PACKAGE LEAFLET: INFORMATION FOR THE USER
CETROTIDE 0.25 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Cetrorelix
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Cetrotide is and what it is used for
2.
What you need to know before you use Cetrotide
3.
How to use Cetrotide
4.
Possible side effects
5
How to store Cetrotide
6.
Contents of the pack and other information
How to mix and inject Cetrotide
1.
WHAT CETROTIDE IS AND WHAT IT IS USED FOR
WHAT CETROTIDE IS
Cetrotide contains a medicine called ‘cetrorelix’. This medicine
stops your body from releasing an egg
from your ovary (ovulation) during your menstrual cycle. Cetrotide
belongs to a group of medicines
called ‘anti-gonadotropin-releasing hormones’.
WHAT CETROTIDE IS USED FOR
Cetrotide is one of the medicines used during ‘assisted reproductive
techniques’ to help you get
pregnant. It stops eggs being released straight away. This is because
if the eggs are released too early
(premature ovulation) it may not be possible for your doctor to
collect them.
HOW CETROTIDE WORKS
Cetrotide blocks a natural hormone in your body called LHRH
(‘luteinising hormone releasing
hormone’).
•
LHRH controls another hormone, called LH (‘luteinising hormone’).
•
LH stimulates ovulation during your menstrual cycle.
This means that Cetrotide stops the chain of events that leads to an
egg being released from your
ovary. When your eggs are ready to be collected, another medicine will
be given to you that will
release 
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Cetrotide 0.25 mg powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 0.25 mg cetrorelix (as acetate).
After reconstitution with the solvent provided, each mL of the
solution contains 0.25 mg cetrorelix.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Appearance of the powder: white lyophilisate
Appearance of the solvent: clear and colourless solution
The pH of the reconstituted solution is 4.0-6.0.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prevention of premature ovulation in patients undergoing a controlled
ovarian stimulation, followed
by oocyte pick-up and assisted reproductive techniques.
In clinical trials Cetrotide was used with human menopausal
gonadotropin (HMG), however, limited
experience with recombinant follicle-stimulating hormone (FSH)
suggested similar efficacy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Cetrotide should only be prescribed by a specialist experienced in
this field.
Posology
The first administration of Cetrotide should be performed under the
supervision of a physician and
under conditions where treatment of possible allergic/pseudo-allergic
reactions (including
life-threatening anaphylaxis) is immediately available. The following
injections may be
self-administered as long as the patient is made aware of the signs
and symptoms that may indicate
hypersensitivity, the consequences of such a reaction and the need for
immediate medical intervention.
The contents of 1 vial (0.25 mg cetrorelix) are to be administered
once daily, at 24 h intervals, either in
the morning or in the evening. Following the first administration, it
is advised that the patient be kept
under medical supervision for 30 minutes to ensure there is no
allergic/pseudo-allergic reaction to the
injection.
_ _
_Elderly _
There is no relevant use of Cetrotide in the geriatric population.
_Paediatric populat
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 12-04-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 19-12-2019
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 12-04-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 12-04-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 12-04-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti